- History of anastrozol in the treatment of breast carcinoma2003 | Faculty of Medicine in Pilsen
- Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes2020 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial +12006 | First Faculty of Medicine
- Aromatase inhibitors and their place in the adjuvant treatment of breast cancer2008 | First Faculty of Medicine
- Anastrozole-mediated modulation of mitochondrial activity by inhibition of mitochondrial permeability transition pore opening: an initial perspective2023 | Faculty of Medicine in Hradec Králové
- Commentary: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial2006 | First Faculty of Medicine
- Anastrozol alone or in combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer2003 | First Faculty of Medicine
- Anastrozol alone or in combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer2003 | Faculty of Physical Education and Sport
- Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial2006 | Faculty of Physical Education and Sport
- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial2014 | First Faculty of Medicine
- Does patient education work in breast cancer? Final results from the global CARIATIDE study2015 | First Faculty of Medicine
- Impact of BOLERO-2 study results on clinical practice and future treatment of postmenopausal patients with advance HR+/HER2- breast cancer2014 | First Faculty of Medicine